SUBSCRIBE
SUBSCRIBE
News   Business   Deals

Johnson & Johnson Says Crucell N.V. Bid Still Valid

October 29, 2010 | 
1 min read
AMSTERDAM, Oct 29 (Reuters) - U.S. healthcare group Johnson & Johnson (JNJ.N) said on Friday it stood by its bid for Crucell (CRCL.AS)(CRXL.O) after the Dutch biotechnology firm halted shipments of two vaccines pending an investigation.
Mergers & acquisitions Europe
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Business handshake trendy halftone art collage banner template. Partnership concept, successful agreement, closing a deal, securing a contract. Modern retro cut out vector illustration
Cancer
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
September 22, 2026
 · 
2 min read
 · 
Tristan Manalac
China flag on bar chart concept with increasing values, economic recovery and business improving after crisis and other catastrophe as economy and businesses reopen again
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
September 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Encountered financial crisis, Businessman stuck in the gap between the stairs and the money bag stock illustration
C-suite
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
September 21, 2026
 · 
5 min read
 · 
Annalee Armstrong
Two men walking on separate winding paths that merge into a single large upward arrow representing business partnership and shared goals, 3d render
Mergers & acquisitions
Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
September 21, 2026
 · 
3 min read
 · 
Tristan Manalac